QURE UNIQURE NV

uniQure Announces Change for its 2020 Annual General Meeting of Shareholders

uniQure Announces Change for its 2020 Annual General Meeting of Shareholders

~ Virtual Meeting Only by Live Audio Webcast – No Physical Meeting Location ~

LEXINGTON, Mass. and AMSTERDAM, June 15, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE) announced today a change to the location and format of its 2020 Annual General Meeting of Shareholders (the “2020 Annual Meeting”). In light of the continuing coronavirus (COVID-19) pandemic and public health concerns, the location and format of the 2020 Annual Meeting will be conducted exclusively by remote communications, via the Internet.

The meeting will continue to be held on Wednesday, June 17, 2020, at 8:30 a.m. Eastern Standard Time/ 2:30 p.m. Central European Summer Time. Shareholders will not be able to attend the 2020 Annual Meeting in person and will not be able to vote their shares in real time, but shareholders of record as of the close of business on May 20, 2020, will be able to participate in the 2020 Annual Meeting through the virtual meeting platform.

To attend the 2020 Annual Meeting, shareholders may visit either the Investors and Newsroom section of the uniQure corporate website, or go directly to and enter the control number included on the notice, proxy card or voting instruction form previously distributed. Those without a control number may attend the 2020 Annual Meeting as guests by logging in to the same virtual meeting platform and following the instructions on the website for guest access. Unlike shareholders with control numbers, guests will not be able to ask questions at the 2020 Annual Meeting.

A replay of the webcast will be available via a link on the uniQure website in the Investors & Newsroom section under Corporate Governance.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.

uniQure Contacts:

FOR INVESTORS:  FOR MEDIA:
   
Maria E. CantorChiara RussoTom Malone   
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
Mobile:  617-680-9452Mobile: 617-306-9137Mobile:339-223-8541

EN
15/06/2020

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In the final meeting minu...

December 4, 2025 1 EN
Free Trial
QURE UNIQURE NV

Uniqure Nv: 1 director

A director at Uniqure Nv sold/sold after exercising options 31,434 shares at 27.260USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

11/11/25 November 11, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Third Quarter 2025 Financial Results and Provides Co...

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update ~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~ ~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with the FDA to define ne...

November 10, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure to Announce Third Quarter 2025 Financial Results

uniQure to Announce Third Quarter 2025 Financial Results ~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at , and followi...

November 6, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD).   Though final meeting minutes have not yet been received, based on the discussions at the m...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch